Why tirzepatide ordering is a protocol-economics problem
Tirzepatide programs run across a wide titration range, and the landed cost per vial can change as the patient escalates. That makes the ordering question economic rather than purely operational: to price a protocol you need the per-vial 503A cost at each step, not a single blended rate. Refill connects you to 503A pharmacies that compound tirzepatide, but concentrations, vial sizes, and rates depend on the specific partner pharmacy, so confirm the per-step economics directly rather than assuming a flat catalog price.
This page covers ordering workflow and economics, not clinical dosing. The titration schedule is a prescriber decision; the platform's job is to make the right vial reach the patient with a correct SIG and to show what each step costs. What you should evaluate is whether the platform surfaces per-vial cost and validation so the protocol orders cleanly and predictably.